Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more
Tourmaline Bio Inc. (TRML) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.078x
Based on the latest financial reports, Tourmaline Bio Inc. (TRML) has a cash flow conversion efficiency ratio of -0.078x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.26 Million) by net assets ($259.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tourmaline Bio Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tourmaline Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tourmaline Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tourmaline Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xencor Inc
NASDAQ:XNCR
|
-0.049x |
|
Antar Chile
SN:ANTARCHILE
|
0.005x |
|
NewtekOne, Inc. 8.50% Fixed Rate Senior Notes due 2031
NASDAQ:NEWTO
|
N/A |
|
Zhongnongfa Seed Industry Group Co Ltd
SHG:600313
|
-0.022x |
|
Appotronics Corp Ltd
SHG:688007
|
0.029x |
|
Jiangsu Rainbow Heavy Industries Co Ltd
SHE:002483
|
0.014x |
|
Lai Yih Footwear Co., Ltd.
TW:6890
|
0.040x |
|
PC Connection Inc
NASDAQ:CNXN
|
0.030x |
Annual Cash Flow Conversion Efficiency for Tourmaline Bio Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tourmaline Bio Inc. from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $300.05 Million | $-77.26 Million | -0.257x | -88.02% |
| 2023-12-31 | $205.04 Million | $-28.08 Million | -0.137x | -141.84% |
| 2022-12-31 | $-19.73 Million | $-6.46 Million | 0.327x | +298.73% |
| 2021-12-31 | $242.81 Million | $-39.99 Million | -0.165x | -26.87% |
| 2020-12-31 | $148.00 Million | $-19.21 Million | -0.130x | +70.90% |
| 2019-12-31 | $39.59 Million | $-17.66 Million | -0.446x | -- |